Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

Blood blood.2024025945.

https://doi.org/10.1182/blood.2024025945

Published: 2024

Includes: Supplemental data

Journal Articles

Impact of Prior Lines of Therapy before Autologous Hematopoietic Cell Transplant on Survival in Standard Risk Multiple Myeloma

Hussein Awada, Ali Hajj Ali, Danai Dima, Craig S Sauter, Louis Williams, Jack Khouri, Shahzad Raza, Sandra Mazzoni, Jason Valent, Christy J. Samaras, Faiz Anwer

Blood (2023) 142 (Supplement 1): 7069.

https://doi.org/10.1182/blood-2023-189995

Published: 2023

Journal Articles

Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma

Danai Dima, James A Davis, Nausheen Ahmed, Aishwarya Sannareddy, Hira Shaikh, Zahra Mahmoudjafari, Jack Khouri, Gurbakhash Kaur, Christopher Strouse, Jason Valent, Larry D. Anderson, Jr., Faiz Anwer, Al-Ola Abdallah, Hamza Hashmi

Blood (2023) 142 (Supplement 1): 91.

https://doi.org/10.1182/blood-2023-180421

Published: 2023

Journal Articles

Safety and Tolerability of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Safety Run-in Results from a Phase 2 Study

Blood (2023) 142 (Supplement 1): 3383.

https://doi.org/10.1182/blood-2023-186997

Published: 2023

Journal Articles

Fludarabine Lymphodepletion Exposure Is Associated with Idecabtagene Vicleucel Toxicity in Relapsed and Refractory Multiple Myeloma Patients: Real-World Experience from the US Myeloma Immunotherapy Consortium

Blood (2023) 142 (Supplement 1): 4880.

https://doi.org/10.1182/blood-2023-187440

Published: 2023

Journal Articles

Trial in Progress: An Open-Label, Multi-Center Phase 2 Study to Assess the Safety and Efficacy of Burixafor (GPC-100) and Propranolol with and without G-CSF for the Mobilization of Stem Cells in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Nina Caculitan, Josephine M. Cardarelli, Jack Khouri, Hyung C Suh, Muthalagu Ramanathan, Ann Woolfrey

Blood (2023) 142 (Supplement 1): 7082.

https://doi.org/10.1182/blood-2023-187191

Published: 2023

Journal Articles

Molecular Expression Differences in Blood Mononuclear Cells in Patients with AL Amyloidosis

David Kaplan, Eric Christian, Jason Valent, Faiz Anwer, Shahzad Raza, Sandra Mazzoni, Christy J. Samaras, Louis S. Williams, Danai Dima, Kelly Shepherd, Jared Fennema, Sherry Fada, Megan Nakashima, Mazen Hanna, Hillard M. Lazarus, Jack Khouri

Blood (2023) 142 (Supplement 1): 5031.

https://doi.org/10.1182/blood-2023-180735

Published: 2023

Journal Articles

Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3499.

https://doi.org/10.1182/blood-2023-187565

Published: 2023

Journal Articles

Impact of Frailty on Outcomes after CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma

James A Davis, Danai Dima, Nausheen Ahmed, Shaun DeJarnette, Joseph P McGuirk, Jack Khouri, Jason Valent, Faiz Anwer, Al-Ola Abdallah, Hamza Hashmi

Blood (2023) 142 (Supplement 1): 3503.

https://doi.org/10.1182/blood-2023-179981

Published: 2023

Journal Articles

Outcomes of Venetoclax-Based Therapy in Patients with Daratumumab-Refractory t(11;14) Positive Light Chain Amyloidosis

Mark Orland, Danai Dima, Fauzia Ullah, Hussein Awada, Diana Basali, Beth M. Faiman, Cynthia Scott, Sandra Mazzoni, Louis S. Williams, Christy J. Samaras, Jason Valent, Faiz Anwer, Shahzad Raza, Jack Khouri

Blood (2023) 142 (Supplement 1): 2031.

https://doi.org/10.1182/blood-2023-183030

Published: 2023

Journal Articles

Pooled Analysis of Safety from Birtamimab Phase 1-3 Studies in Patients with Light Chain (AL) Amyloidosis

Vaishali Sanchorawala, Ashutosh D Wechalekar, Efstathios Kastritis, Giovanni Palladini, Stefan Schönland, Raymond Comenzo, Anita D'Souza, Jack Khouri, Victor Jimenez-Zepeda, Katherine Ingrid Sprinz, Heather Hao, Wenying Huang, Laura Governale Aubrey, Morie A. Gertz

Blood (2023) 142 (Supplement 1): 3409.

https://doi.org/10.1182/blood-2023-174703

Published: 2023

Journal Articles

Outcomes of Lymphoma and Multiple Myeloma Patients Following Inpatient Antineoplastic Treatment

Blood (2023) 142 (Supplement 1): 7245.

https://doi.org/10.1182/blood-2023-190304

Published: 2023

Journal Articles

Insights into Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: A 12-Year Experience of a Large Academic Center

Danai Dima, Fauzia Ullah, Serhan Unlu, Diana Basali, Mahir Khan, Abdullah Saeed Khan, Xuefei Jia, Majid Jaberi-Douraki, Beth M. Faiman, Sandra Mazzoni, Louis S. Williams, Christy J. Samaras, Jason Valent, Faiz Anwer, Jack Khouri, Shahzad Raza

Blood (2023) 142 (Supplement 1): 3407.

https://doi.org/10.1182/blood-2023-181365

Published: 2023

Journal Articles

Outcomes of Salvage VDT-PACE-like Regimens in Relapsed-Refractory Multiple Myeloma: 10-Year Experience of a Large Academic Institution

Arooj Ahmed, Danai Dima, Kerri Row, Fauzia Ullah, Hussein Awada, Diana Basali, Heena Kurish, Mikhaila Rice, Joslyn Rudoni, Marissa Duco, Beth M. Faiman, Jack Khouri, Sandra Mazzoni, Louis S. Williams, Shahzad Raza, Christy J. Samaras, Jason Valent, Faiz Anwer

Blood (2023) 142 (Supplement 1): 4724.

https://doi.org/10.1182/blood-2023-182972

Published: 2023

Journal Articles

First Report on the Effects of Lisaftoclax (APG-2575) in Combination with Novel Therapeutic Regimens in Patients with Relapsed or Refractory Multiple Myeloma (R/R MM) or Immunoglobulin Light-Chain (Amyloid Light-Chain [AL]) Amyloidosis

Sikander Ailawadhi, Asher A. Chanan-Khan, Costas K. Yannakou, Simon Gibbs, Jack Khouri, Zi Chen, Huanshan Guo, Mingyu Li, Mohammad Ahmad, Cunlin Wang, Dajun Yang, Yifan Zhai

Blood (2023) 142 (Supplement 1): 2016.

https://doi.org/10.1182/blood-2023-188122

Published: 2023

Journal Articles

An Ensemble Machine Learning Model Using Gradient Boosting Identifies Patients with Disease Progression in Newly Diagnosed Multiple Myeloma

Louis S. Williams, Bardia Khosravi, Marko Velimirovic, Jack Khouri, Shahzad Raza, Sandra Mazzoni, Christy J. Samaras, Hussein Awada, Danai Dima, Jason Valent, Faiz Anwer

Blood (2023) 142 (Supplement 1): 1990.

https://doi.org/10.1182/blood-2023-188762

Published: 2023

Journal Articles

Toxicity and Efficacy Outcomes of Teclistamab in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Above the Age of 70 Years: A Multicenter Study

Danai Dima, Aishwarya Sannareddy, Nausheen Ahmed, James A Davis, Hira Shaikh, Zahra Mahmoudjafari, Marissa Duco, Jack Khouri, Gurbakhash Kaur, Jonathan Lochner, Faiz Anwer, Aimaz Afrough, Jason Valent, Hamza Hashmi, Al-Ola Abdallah

Blood (2023) 142 (Supplement 1): 3330.

https://doi.org/10.1182/blood-2023-180458

Published: 2023

Journal Articles

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Not Meeting the Karmma Trial Eligibility Criteria: A Real-World Multicenter Study

Danai Dima, Aliya Rashid, James A Davis, Hussein Awada, Al-Ola Abdallah, Hong Li, Shaun DeJarnette, Leyla Shune, Jack Khouri, Hamza Hashmi, Joseph P McGuirk, Faiz Anwer, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 4885.

https://doi.org/10.1182/blood-2023-180368

Published: 2023

Journal Articles

Outcomes of BCMA-Directed Chimeric Antigen Receptor T-Cell (CART) Therapy in Patients with Relapse-Refractory Multiple Myeloma with Extramedullary Disease

Danai Dima, James A Davis, Aliya Rashid, Mikhaila Rice, Shaun DeJarnette, Leyla Shune, Jack Khouri, Shahzad Raza, Joseph P McGuirk, Faiz Anwer, Nausheen Ahmed, Al-Ola Abdallah, Hamza Hashmi

Blood (2023) 142 (Supplement 1): 4882.

https://doi.org/10.1182/blood-2023-181331

Published: 2023

Journal Articles

Neighborhood Socioeconomic Disadvantage and Distance from Treatment Center Do Not Impact Survival Outcomes of Patients with Non-Hodgkin Lymphoma and Multiple Myeloma Treated with CAR T-Cell Therapies

Agrima Mian, Danai Dima, Betty K. Hamilton, Allison Winter, Jack Khouri, Louis S. Williams, Shahzad Raza, Deepa Jagadeesh, Aaron T. Gerds, Robert M. Dean, Matt Kalaycio, Claudio Brunstein, Craig S Sauter, Faiz Anwer, Brian T. Hill, Paolo Caimi

Blood (2023) 142 (Supplement 1): 7399.

https://doi.org/10.1182/blood-2023-188712

Published: 2023

NARROW

Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

Impact of Prior Lines of Therapy before Autologous Hematopoietic Cell Transplant on Survival in Standard Risk Multiple Myeloma

Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma

Safety and Tolerability of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Safety Run-in Results from a Phase 2 Study

Fludarabine Lymphodepletion Exposure Is Associated with Idecabtagene Vicleucel Toxicity in Relapsed and Refractory Multiple Myeloma Patients: Real-World Experience from the US Myeloma Immunotherapy Consortium

Trial in Progress: An Open-Label, Multi-Center Phase 2 Study to Assess the Safety and Efficacy of Burixafor (GPC-100) and Propranolol with and without G-CSF for the Mobilization of Stem Cells in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Molecular Expression Differences in Blood Mononuclear Cells in Patients with AL Amyloidosis

Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma

Impact of Frailty on Outcomes after CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma

Outcomes of Venetoclax-Based Therapy in Patients with Daratumumab-Refractory t(11;14) Positive Light Chain Amyloidosis

Pooled Analysis of Safety from Birtamimab Phase 1-3 Studies in Patients with Light Chain (AL) Amyloidosis

Outcomes of Lymphoma and Multiple Myeloma Patients Following Inpatient Antineoplastic Treatment

Insights into Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: A 12-Year Experience of a Large Academic Center

Outcomes of Salvage VDT-PACE-like Regimens in Relapsed-Refractory Multiple Myeloma: 10-Year Experience of a Large Academic Institution

First Report on the Effects of Lisaftoclax (APG-2575) in Combination with Novel Therapeutic Regimens in Patients with Relapsed or Refractory Multiple Myeloma (R/R MM) or Immunoglobulin Light-Chain (Amyloid Light-Chain [AL]) Amyloidosis

An Ensemble Machine Learning Model Using Gradient Boosting Identifies Patients with Disease Progression in Newly Diagnosed Multiple Myeloma

Toxicity and Efficacy Outcomes of Teclistamab in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Above the Age of 70 Years: A Multicenter Study

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Not Meeting the Karmma Trial Eligibility Criteria: A Real-World Multicenter Study

Outcomes of BCMA-Directed Chimeric Antigen Receptor T-Cell (CART) Therapy in Patients with Relapse-Refractory Multiple Myeloma with Extramedullary Disease

Neighborhood Socioeconomic Disadvantage and Distance from Treatment Center Do Not Impact Survival Outcomes of Patients with Non-Hodgkin Lymphoma and Multiple Myeloma Treated with CAR T-Cell Therapies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only